Join the Ozanimod group to help and get support from people like you.
Ozanimod News
Women Less Likely to Get Certain MS Meds Than Men
THURSDAY, July 31, 2025 — Women are less likely than men to receive multiple sclerosis (MS) meds that could help them manage the disease and delay disability, a new report finds. It could be that s...
Women With MS Less Likely Than Men to Receive Disease-Modifying Therapies
THURSDAY, July 31, 2025 – Women with multiple sclerosis (MS) are less likely to receive disease-modifying therapies (DMTs) than men, according to a study published online July 30 in Neurology....
FDA Approves Bristol Myers Squibb’s Zeposia (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
PRINCETON, N.J.--(BUSINESS WIRE) May 27, 2021 – Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment...
FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of...
Further information
Related condition support groups
Multiple Sclerosis, Ulcerative Colitis